Renal Cell Carcinoma
López, José I.
Renal Cell Carcinoma - MDPI - Multidisciplinary Digital Publishing Institute 2020 - 1 electronic resource (500 p.)
Open Access
Renal cancer is a health problem of major concern worldwide. Although tyrosine kinase inhibitors and immune check-point blockade treatments, alone or in combination, are giving promising results, failures are quite frequent due to intratumor heterogeneity and to the acquisition of drug resistance. The spectrum of renal cell carcinoma subtypes is wide. Up to 70–80% of renal tumors are clear cell renal cell carcinomas, a clinically aggressive tumor subtype linked to VHL gene inactivation. Next in frequency, the papillary renal cell carcinoma category encompasses an intricate puzzle of classic and newly described entities with poorly defined limits, some of them pending definite clarification. Likewise, the chromophobe–oncocytoma duality, the so-called hybrid tumors and oncocytic neoplasms, remain to be well profiled. Finally, a growing list of very uncommon renal tumors linked to specific molecular signatures fulfill the current portrait of renal cell neoplasia. This Special Issue of Cancers regards RCC from very different perspectives, from the intimate basic mechanisms governing this disease to the clinical practice principles of their diagnoses and treatments. The interested reader will have the opportunity to contact with some of the most recent findings and will be updated with excellent reviews.
Creative Commons
English
books978-3-03928-639-3 9783039286386 9783039286393
10.3390/books978-3-03928-639-3 doi
N-glycomapping n/a SMAD proteins patient survival pro-IL-1? survival prediction inflammation markers tumor migration prognostic factors practical approach circular RNAs in a clinico-genomic predictive model glycomarkers review nephrectomy uric acid VEGF inhibitors metabolic reprogramming collecting duct carcinoma curcumin metabolome profiling identification of circular RNAs IL-2 experimental validation of circular RNA Raf/MEK/ERK HOT PI3K/Akt/mTOR pentose phosphate pathway kidney cancer LOT mutation RCC polybromo-1 pale cell MMP-9 gene expression recurrence free survival chromosomal loss IL-1? chronic kidney disease glutathione transferase omega 2 label-free glutathione transferase omega 1 emerging entity copy number alteration FOXO3 predictive role tumor slice culture tyrosine kinase inhibitors PPP ESC CDKN1A expression metastasis PD-L1 diagnostic and prognostic markers EVI1 copy number loss RNA sequencing NK cells glutathione metabolism clear cell renal cell carcinoma renal cell cancer proliferation eosinophilic variant Xp11 translocation renal cell carcinoma prognosis invasion immune infiltration IL4R? FISH 11) translocation renal cell carcinoma tumor microenvironment metabolome hyperosmolality toxicity ALK drug sensitivity t(6 copy number analysis urine genetic association polymorphism solute carrier proteins kidney metastatic ccRCC molecular genetic features recurrence-free survival chromophobe renal cell carcinoma unclassified renal tumor overall survival mTOR inhibitors mTOR JAK2 von Hippel–Lindau miR-155-5p glycoproteomics PBRM1 miR-133b survival TFE3 TFEB oncocytic renal tumor immune checkpoint inhibitors biomarker MMP10 TCGA ghrelin EMT like checkpoint inhibitors MiT family translocation renal cell carcinoma gene signature sarcomatoid transforming growth factor beta clear cell Renal Cell Carcinoma tumor adhesion renal cancer unclassified renal cell carcinoma Papillary renal cell carcinoma (pRCC) miR-146a-5p renal cell everolimus integrins cytoreductive nephrectomy immunotherapy predictive factors immunohistochemistry MTA2 IL13R?1 targeted therapy intratumour heterogeneity aurora A TCA cycle AMP-activated protein kinases cancer-specific survival programmed death-ligand 1 efficacy renal cell carcinoma anaplastic lymphoma kinase rearrangement TFEB-amplified renal cell carcinoma statins cancer immunotherapy microRNA new entity proteome profiling
Renal Cell Carcinoma - MDPI - Multidisciplinary Digital Publishing Institute 2020 - 1 electronic resource (500 p.)
Open Access
Renal cancer is a health problem of major concern worldwide. Although tyrosine kinase inhibitors and immune check-point blockade treatments, alone or in combination, are giving promising results, failures are quite frequent due to intratumor heterogeneity and to the acquisition of drug resistance. The spectrum of renal cell carcinoma subtypes is wide. Up to 70–80% of renal tumors are clear cell renal cell carcinomas, a clinically aggressive tumor subtype linked to VHL gene inactivation. Next in frequency, the papillary renal cell carcinoma category encompasses an intricate puzzle of classic and newly described entities with poorly defined limits, some of them pending definite clarification. Likewise, the chromophobe–oncocytoma duality, the so-called hybrid tumors and oncocytic neoplasms, remain to be well profiled. Finally, a growing list of very uncommon renal tumors linked to specific molecular signatures fulfill the current portrait of renal cell neoplasia. This Special Issue of Cancers regards RCC from very different perspectives, from the intimate basic mechanisms governing this disease to the clinical practice principles of their diagnoses and treatments. The interested reader will have the opportunity to contact with some of the most recent findings and will be updated with excellent reviews.
Creative Commons
English
books978-3-03928-639-3 9783039286386 9783039286393
10.3390/books978-3-03928-639-3 doi
N-glycomapping n/a SMAD proteins patient survival pro-IL-1? survival prediction inflammation markers tumor migration prognostic factors practical approach circular RNAs in a clinico-genomic predictive model glycomarkers review nephrectomy uric acid VEGF inhibitors metabolic reprogramming collecting duct carcinoma curcumin metabolome profiling identification of circular RNAs IL-2 experimental validation of circular RNA Raf/MEK/ERK HOT PI3K/Akt/mTOR pentose phosphate pathway kidney cancer LOT mutation RCC polybromo-1 pale cell MMP-9 gene expression recurrence free survival chromosomal loss IL-1? chronic kidney disease glutathione transferase omega 2 label-free glutathione transferase omega 1 emerging entity copy number alteration FOXO3 predictive role tumor slice culture tyrosine kinase inhibitors PPP ESC CDKN1A expression metastasis PD-L1 diagnostic and prognostic markers EVI1 copy number loss RNA sequencing NK cells glutathione metabolism clear cell renal cell carcinoma renal cell cancer proliferation eosinophilic variant Xp11 translocation renal cell carcinoma prognosis invasion immune infiltration IL4R? FISH 11) translocation renal cell carcinoma tumor microenvironment metabolome hyperosmolality toxicity ALK drug sensitivity t(6 copy number analysis urine genetic association polymorphism solute carrier proteins kidney metastatic ccRCC molecular genetic features recurrence-free survival chromophobe renal cell carcinoma unclassified renal tumor overall survival mTOR inhibitors mTOR JAK2 von Hippel–Lindau miR-155-5p glycoproteomics PBRM1 miR-133b survival TFE3 TFEB oncocytic renal tumor immune checkpoint inhibitors biomarker MMP10 TCGA ghrelin EMT like checkpoint inhibitors MiT family translocation renal cell carcinoma gene signature sarcomatoid transforming growth factor beta clear cell Renal Cell Carcinoma tumor adhesion renal cancer unclassified renal cell carcinoma Papillary renal cell carcinoma (pRCC) miR-146a-5p renal cell everolimus integrins cytoreductive nephrectomy immunotherapy predictive factors immunohistochemistry MTA2 IL13R?1 targeted therapy intratumour heterogeneity aurora A TCA cycle AMP-activated protein kinases cancer-specific survival programmed death-ligand 1 efficacy renal cell carcinoma anaplastic lymphoma kinase rearrangement TFEB-amplified renal cell carcinoma statins cancer immunotherapy microRNA new entity proteome profiling